Marc Geirnaert
Marc Geirnaert publishes mostly in Oncology, Economics and Econometrics and Genetics, on topics such as Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research and Economic and Financial Impacts of Cancer.
- World rank
- #4,575,554 of 7,710,434 ranked researchers
- Rank in Canada
- #138,028 of 183,316
- Works
- 24
- Citations
- 140
- Citations per work
- 5.8
What does Marc Geirnaert research?
Marc Geirnaert's work is mostly in Medicine (42%), Economics, Econometrics and Finance (19%), Immunology and Microbiology (7%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1041.7%
- Medicine1041.7%
- Everything else832.0%
- Social Sciences519.4%
- Life Sciences26.9%
- 1Oncology21% of their works
- 2Economics and Econometrics19% of their works
- 3Genetics10% of their works
- 4Immunology7% of their works
- 5Pulmonary and Respiratory Medicine6% of their works
- 6Hematology6% of their works
Research topics
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Lymphoma Diagnosis and Treatment
- Pharmaceutical Economics and Policy
- Immunodeficiency and Autoimmune Disorders
- Multiple Myeloma Research and Treatments
Which keywords describe Marc Geirnaert's research?
The keywords of their largest research topics: Lymphoma, Rituximab, CAR T Cells, Chimeric Antigen Receptor, Chronic Lymphocytic Leukemia, Cost of Care, Financial Toxicity and Genomic Aberrations.
- Primary Immunodeficiency
- Genetic Mutations
- Molecular Profiling
- Drug Development Costs
- Quality of Life
- Genomic Aberrations
- Cost of Care
- Chimeric Antigen Receptor
- Rituximab
- Lymphoma
- CAR T Cells
- Chronic Lymphocytic Leukemia
- Financial Toxicity
- Cost-effectiveness Analysis
- Classification
- Generic Drugs
- Diagnosis Criteria
- International Myeloma Working Group
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 18 words, with their numbers
- Lymphoma92 topics
- Rituximab92 topics
- CAR T Cells61 topic
- Chimeric Antigen Receptor61 topic
- Chronic Lymphocytic Leukemia61 topic
- Cost of Care61 topic
- Financial Toxicity61 topic
- Genomic Aberrations61 topic
- Cost-effectiveness Analysis51 topic
- Quality of Life51 topic
- Classification31 topic
- Drug Development Costs31 topic
- Generic Drugs31 topic
- Molecular Profiling31 topic
- Diagnosis Criteria21 topic
- Genetic Mutations21 topic
- International Myeloma Working Group21 topic
- Primary Immunodeficiency21 topic
Where does Marc Geirnaert work?
Marc Geirnaert's main affiliation in the publication record is CancerCare Manitoba, Canada.
How many publications and citations does Marc Geirnaert have?
OpenAlex counts 24 works and 140 citations for Marc Geirnaert, an h-index of 8, ranking #4,575,554 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Marc Geirnaert. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.